- Home
- RVPHW vs LPL Comparison
RVPHW vs LPL Comparison
Compare RVPHW & LPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVPHW
- LPL
- Stock Information
- Founded
- RVPHW 2018
- LPL 1985
- Country
- RVPHW United States
- LPL South Korea
- Employees
- RVPHW 15
- LPL N/A
- Industry
- RVPHW Biotechnology: Pharmaceutical Preparations
- LPL Industrial Machinery/Components
- Sector
- RVPHW Health Care
- LPL Technology
- Exchange
- RVPHW Nasdaq
- LPL Nasdaq
- Market Cap
- RVPHW N/A
- LPL N/A
- IPO Year
- RVPHW N/A
- LPL 2004
- Fundamental
- Price
- RVPHW $0.06
- LPL $2.90
- Analyst Decision
- RVPHW
- LPL Sell
- Analyst Count
- RVPHW 0
- LPL 2
- Target Price
- RVPHW N/A
- LPL N/A
- AVG Volume (30 Days)
- RVPHW 22.4K
- LPL 390.4K
- Earning Date
- RVPHW 03-14-2025
- LPL 05-02-2025
- Dividend Yield
- RVPHW N/A
- LPL N/A
- EPS Growth
- RVPHW N/A
- LPL N/A
- EPS
- RVPHW N/A
- LPL N/A
- Revenue
- RVPHW N/A
- LPL $18,624,457,609.00
- Revenue This Year
- RVPHW N/A
- LPL $2.57
- Revenue Next Year
- RVPHW N/A
- LPL $0.51
- P/E Ratio
- RVPHW N/A
- LPL N/A
- Revenue Growth
- RVPHW N/A
- LPL 24.77
- 52 Week Low
- RVPHW $0.13
- LPL $2.43
- 52 Week High
- RVPHW $0.15
- LPL $4.86
- Technical
- Relative Strength Index (RSI)
- RVPHW N/A
- LPL 48.35
- Support Level
- RVPHW N/A
- LPL $2.82
- Resistance Level
- RVPHW N/A
- LPL $2.95
- Average True Range (ATR)
- RVPHW 0.00
- LPL 0.14
- MACD
- RVPHW 0.00
- LPL 0.03
- Stochastic Oscillator
- RVPHW 0.00
- LPL 90.38
About RVPHW Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.